Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Incyte Corp (INCY)

86.55   1.48 (1.74%) 09-27 23:17
Open: 84.68 Pre. Close: 85.07
High: 87.34 Low: 84.06
Volume: 1,378,117 Market Cap: 18,928M
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 1,367 full-time employees. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The firm also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 87.465 - 87.955 87.955 - 88.403
Low: 82.78 - 83.414 83.414 - 83.995
Close: 85.618 - 86.55 86.55 - 87.404

Technical analysis

as of: 2020-09-25 4:31:26 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 106.87     One year: 113.02
Support: Support1: 82.98    Support2: 69.04
Resistance: Resistance1: 91.50    Resistance2: 96.76
Pivot: 88.64
Moving Average: MA(5): 85.98     MA(20): 89.99
MA(100): 97.40     MA(250): 88.52
MACD: MACD(12,26): -2.57     Signal(9): -2.34
Stochastic oscillator: %K(14,3): 19.11     %D(3): 15.22
RSI: RSI(14): 40.63
52-week: High: 110.37  Low: 62.48  Change(%): 16.6
Average Vol(K): 3-Month: 118460  10-Days: 137686

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
INCY has closed above bottom band by 28.4%. Bollinger Bands are 14.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 25 Sep 2020
Credit Suisse Stick to Their Hold Rating for Incyte Corp - Investing.com

Fri, 25 Sep 2020
Incyte Corporation (INCY) return on Assets touches 14.72: These Shares are Poised for Major Movement - News Daemon

Thu, 24 Sep 2020
Analyst Rating: Will Incyte Corporation (INCY) Stock Outperform the Market? - InvestorsObserver

Mon, 21 Sep 2020
The Forecast Just Changed on Incyte Corporation (NASDAQ:INCY) - The Oracle Dispatch

Fri, 18 Sep 2020
Incyte Corporation (INCY) Stock: Is It a Good Pick? - InvestorsObserver

Fri, 18 Sep 2020
Why is Incyte Corporation (INCY) up 15.13% from the day 1 this year? - The InvestChronicle

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 217
Shares Float (M) 185
% Held by Insiders 0.66
% Held by Institutions 92.40
Shares Short (K) 5,280
Shares Short P. Month (K) 4,860

Stock Financials

EPS -0.890
EPS Est This Year -0.810
EPS Est Next Year 0.420
Book Value (p.s.) 10.750
Profit Margin -8.00
Operating Margin -7.77
Return on Assets (ttm) -3.8
Return on Equity (ttm) -8.3
Qtrly Rev. Growth 29.8
Gross Profit (p.s.) 4.096
Sales Per Share 10.995
EBITDA (p.s.) -0.607
Qtrly Earnings Growth 175.60
Operating Cash Flow (M) -12
Levered Free Cash Flow (M) 65

Stock Valuations

PE Ratio -97.25
PEG Ratio 0.77
Price to Book value 8.05
Price to Sales 7.87
Price to Cash Flow -1567.78

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.